0001140361-22-029239 | 10-Q | XBRL Viewer

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2022	Aug. 05, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Document Transition Report	false
Entity File Number	001-35312
Entity Registrant Name	NUWELLIS, INC.
Entity Central Index Key	0001506492
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	68-0533453
Entity Address, Address Line One	12988 Valley View Road
Entity Address, City or Town	Eden Prairie
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55344
City Area Code	952
Local Phone Number	345-4200
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NUWE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,537,606

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 15,345	$ 24,205
Accounts receivable	1,313	750
Inventories	3,010	2,843
Other current assets	252	328
Total current assets	19,920	28,126
Property, plant and equipment, net	1,063	1,188
Operating lease right-of-use asset	994	1,082
Other assets	21	21
TOTAL ASSETS	21,998	30,417
Current liabilities
Accounts payable	1,550	1,414
Accrued compensation	1,633	1,664
Current portion of operating lease liability	186	167
Current portion of finance lease liability	27	26
Other current liabilities	63	36
Total current liabilities	3,459	3,307
Operating lease liability	860	956
Finance lease liability	15	28
Other long-term liability	0	179
Total liabilities	4,334	4,470
Commitments and contingencies
Stockholders' equity
Preferred stock	0	0
Common stock as of June 30, 2022 and December 31, 2021, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 10,537,606 shares	1	1
Additional paid-in capital	279,350	278,873
Accumulated other comprehensive income:
Foreign currency translation adjustment	(12)	(11)
Accumulated deficit	(261,675)	(252,916)
Total stockholders' equity	17,664	25,947
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	21,998	30,417
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	$ 0	$ 0

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	39,969,873	39,969,873
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	10,537,606	10,537,606
Common stock, shares outstanding (in shares)	10,537,606	10,537,606
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	30,000	30,000
Preferred stock, shares outstanding (in shares)	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	127	127
Preferred stock, shares issued (in shares)	127	127
Preferred stock, shares outstanding (in shares)	127	127

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Net sales	$ 2,213	$ 2,508	$ 4,139	$ 4,426
Cost of goods sold	1,150	997	1,974	1,949
Gross profit	1,063	1,511	2,165	2,477
Operating expenses:
Selling, general and administrative	4,257	5,063	8,669	10,300
Research and development	1,107	1,174	2,213	2,121
Total operating expenses	5,364	6,237	10,882	12,421
Loss from operations	(4,301)	(4,726)	(8,717)	(9,944)
Other income (expense), net	17	(2)	(38)	(3)
Loss before income taxes	(4,284)	(4,728)	(8,755)	(9,947)
Income tax expense	(2)	(3)	(4)	(5)
Net loss	$ (4,286)	$ (4,731)	$ (8,759)	$ (9,952)
Basic loss per share (in dollars per share)	$ (0.41)	$ (0.72)	$ (0.83)	$ (2.04)
Diluted loss per share (in dollars per share)	$ (0.41)	$ (0.72)	$ (0.83)	$ (2.04)
Weighted average shares outstanding - basic (in shares)	10,538	6,532	10,538	4,887
Weighted average shares outstanding - diluted (in shares)	10,538	6,532	10,538	4,887
Other comprehensive loss:
Foreign currency translation adjustments	$ 1	$ 0	$ (1)	$ (3)
Total comprehensive loss	$ (4,285)	$ (4,731)	$ (8,760)	$ (9,955)

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2020	$ 0	$ 249,663	$ (7)	$ (233,338)	$ 16,318
Balance (in shares) at Dec. 31, 2020	2,736,060
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(5,221)	(5,221)
Unrealized foreign currency translation adjustments	0	0	(3)	0	(3)
Stock-based compensation, net	$ 0	355	0	0	355
Stock-based compensation, net (in shares)	0
Issuance of common, net	$ 0	18,902	0	0	18,902
Issuance of common, net (in shares)	3,795,816
Exercise of warrants	$ 0	1	0	0	1
Exercise of warrants (in shares)	66
Balance at Mar. 31, 2021	$ 0	268,921	(10)	(238,559)	30,352
Balance (in shares) at Mar. 31, 2021	6,531,942
Balance at Dec. 31, 2020	$ 0	249,663	(7)	(233,338)	16,318
Balance (in shares) at Dec. 31, 2020	2,736,060
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(9,952)
Unrealized foreign currency translation adjustments					(3)
Balance at Jun. 30, 2021	$ 0	269,296	(10)	(243,290)	25,996
Balance (in shares) at Jun. 30, 2021	6,532,018
Balance at Mar. 31, 2021	$ 0	268,921	(10)	(238,559)	30,352
Balance (in shares) at Mar. 31, 2021	6,531,942
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(4,731)	(4,731)
Unrealized foreign currency translation adjustments	0	0	0	0	0
Stock-based compensation, net	$ 0	381	0	0	381
Stock-based compensation, net (in shares)	0
Issuance costs related to common stock offerings	$ 0	(6)	0	0	(6)
Exercise of warrants	$ 0	0	0	0	0
Exercise of warrants (in shares)	76
Balance at Jun. 30, 2021	$ 0	269,296	(10)	(243,290)	25,996
Balance (in shares) at Jun. 30, 2021	6,532,018
Balance at Dec. 31, 2021	$ 1	278,873	(11)	(252,916)	25,947
Balance (in shares) at Dec. 31, 2021	10,537,606
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(4,473)	(4,473)
Unrealized foreign currency translation adjustments	0	0	(2)	0	(2)
Stock-based compensation, net	$ 0	241	0	0	241
Stock-based compensation, net (in shares)	0
Balance at Mar. 31, 2022	$ 1	279,114	(13)	(257,389)	21,713
Balance (in shares) at Mar. 31, 2022	10,537,606
Balance at Dec. 31, 2021	$ 1	278,873	(11)	(252,916)	25,947
Balance (in shares) at Dec. 31, 2021	10,537,606
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(8,759)
Unrealized foreign currency translation adjustments					(1)
Balance at Jun. 30, 2022	$ 1	279,350	(12)	(261,675)	17,664
Balance (in shares) at Jun. 30, 2022	10,537,606
Balance at Mar. 31, 2022	$ 1	279,114	(13)	(257,389)	21,713
Balance (in shares) at Mar. 31, 2022	10,537,606
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(4,286)	(4,286)
Unrealized foreign currency translation adjustments	0	0	1	0	1
Stock-based compensation, net	$ 0	236	0	0	236
Stock-based compensation, net (in shares)	0
Balance at Jun. 30, 2022	$ 1	$ 279,350	$ (12)	$ (261,675)	$ 17,664
Balance (in shares) at Jun. 30, 2022	10,537,606

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating Activities:
Net loss	$ (8,759,000)	$ (9,952,000)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization	206,000	256,000
Stock-based compensation expense, net	477,000	736,000
Changes in operating assets and liabilities:
Accounts receivable	(563,000)	(272,000)
Inventory	(167,000)	122,000
Other current assets	76,000	(176,000)
Other assets and liabilities	(152,000)	9,000
Accounts payable and accrued expenses	117,000	75,000
Net cash used in operating activities	(8,765,000)	(9,202,000)
Investing Activities:
Purchases of property and equipment	(81,000)	(137,000)
Net cash used in investing activities	(81,000)	(137,000)
Financing Activities:
Proceeds from public stock offerings, net	0	18,896,000
Proceeds from warrant exercises	0	1,300
Payments on finance lease liability	(13,000)	(14,000)
Net cash provided (used in) by financing activities	(13,000)	18,883,000
Effect of exchange rate changes on cash	(1,000)	(3,000)
Net increase (decrease) in cash and cash equivalents	(8,860,000)	9,541,000
Cash and cash equivalents - beginning of period	24,205,000	14,437,000
Cash and cash equivalents - end of period	15,345,000	23,978,000
Supplemental cash flow information
Inventory transferred to property, plant and equipment	$ 0	$ 179,000

Nature of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2022

Nature of Business and Basis of Presentation [Abstract]

Nature of Business and Basis of Presentation

Note 1 – Nature of Business and Basis of Presentation

Nature of Business: Nuwellis, Inc. (the “Company”) is a medical device company focused on developing, manufacturing and commercializing the Aquadex FlexFlow® and Aquadex SmartFlow® systems (collectively, the “Aquadex System”) for ultrafiltration therapy. The Aquadex System is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20kg or more whose fluid overload is unresponsive to medical management, including diuretics. Nuwellis, Inc. is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Ireland. The Company’s common stock began trading on the Nasdaq Stock Market in February 2012.

In August 2016, the Company acquired the business associated with the Aquadex System (the “Aquadex Business”) from a subsidiary of Baxter International, Inc. (“Baxter”), and refocused its strategy to fully devote its resources to the Aquadex Business. On April 27, 2021, the Company announced that it was changing its name from CHF Solutions, Inc. to Nuwellis, Inc. to reflect the expansion of its customer base from treating fluid imbalance resulting from congestive heart failure to also include critical care and pediatric applications.

Principles of Consolidation: The accompanying condensed consolidated balance sheet as of June 30, 2022, which has been derived from the consolidated audited financial statements and the unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information and note disclosures normally included in the audited annual consolidated financial statements have been condensed or omitted pursuant to those rules and regulations. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive loss, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the year as a whole. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates.

These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Going Concern: The Company’s consolidated financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2021, and 2020 and through June 30, 2022, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. As of June 30, 2022, the Company had an accumulated deficit of $261.7 million and it expects to incur losses for the immediate future. To date, the Company has been funded by equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably. These factors raise substantial doubt about the Company’s ability to continue as a going concern through the next twelve months.

The Company became a revenue generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in expanding its sales and marketing capabilities, purchasing inventory, manufacturing components, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex System. This will require the Company to succeed in training personnel at hospitals and in outpatient care settings, and effectively and efficiently manufacturing, marketing and distributing the Aquadex System and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability.

During 2021, the Company closed on underwritten public equity offerings for aggregate net proceeds of approximately $27.9 million after deducting the underwriting discounts and commissions and other costs associated with the offerings. In addition, during 2021 we received approximately $1,300 in proceeds from the exercise of investor warrants. See Note 3—Stockholders’ Equity for additional related disclosure. The Company will require additional funding to grow its Aquadex Business, which may not be available on terms favorable to the Company, or at all. The Company may receive those funds from the proceeds from future warrant exercises, issuances of equity securities, or other financing transactions. Should warrant exercises not materialize or future capital raising be unsuccessful, the Company may not be able to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.

The Company believes that its existing capital resources will be sufficient to support its operating plan through June 30, 2023. However, the Company may seek to raise additional capital to support its growth or other strategic initiatives through debt, equity or a combination thereof. There can be no assurance the Company will be successful in raising additional capital.

Revenue Recognition: The Company recognizes revenue in accordance with Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers. Accordingly, the Company recognizes revenue when its customers obtain control of its products or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods and services. See Note 2 – Revenue Recognition below for additional disclosures. For the three months ended June 30, 2022, three customers represented 14%, 13% and 10% of net sales. For the six months ended June 30, 2022, two customers each represented 14% and 12% of net sales. For the three months ended June 30, 2021, no customer represented over 10% of net sales. For the six months ended June 30, 2021, two customers each represented 11% of net sales.

Accounts Receivable: Accounts receivable are unsecured, are recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of collectability, historical experience, and management’s evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date the Company has not experienced any write-offs or significant deterioration of the aging of its accounts receivable, and therefore, no allowance for doubtful accounts was considered necessary as of June 30, 2022, or December 31, 2021. As of June, 30, 2022, two customers represented 19% and 16% of the accounts receivable balance. As of December 31, 2021, two customers represented 12% and 11% of the accounts receivable balance.

Inventories: Inventories represent finished goods purchased from the Company’s suppliers and are recorded as the lower of cost or net realizable value using the first-in-first out method. Overhead is allocated to manufactured finished goods inventory based on the normal capacity of the Company’s production facilities. Abnormal amounts of overhead, if any, are expensed as incurred. Inventories consisted of the following:

(in thousands)	June 30, 2022		December 31, 2021
Finished Goods	$	1,196	$	1,409
Work in Process		172		276
Raw Materials		1,642		1,158
Total	$	3,010	$	2,843

Loss per share: Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. The net loss allocable to common stockholders for the six months ended June 30, 2021 includes a deemed dividend of $33,000 that resulted from the change in the exercise price of warrants as a result of the March 2021 offering. See Note 3 – Stockholders’ Equity below for additional disclosures.

Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	June 30,
	2022		2021

Stock options		1,197,892		812,561
Warrants to purchase common stock		1,630,627		1,631,806
Series F convertible preferred stock		50,800		23,114
Total		2,879,319		2,467,481

The following table reconciles reported net loss with reported net loss per share for each of the three and six months ended June 30:

	Three months ended June 30,						Six months ended June 30,
	2022			2021			2022			2021
(in thousands, except per share amounts)
Net loss	$	(4,286	)	$	(4,731	)	$	(8,759	)	$	(9,952	)
Deemed dividend to preferred shareholders (see note 3)		—			—			—			(33	)
Net loss after deemed dividend		(4,286	)		(4,731	)		(8,759	)		(9,985	)
Weighted average shares outstanding		10,538			6,532			10,538			4,887
Basic and diluted loss per share	$	(0.41	)	$	(0.72	)	$	(0.83	)	$	(2.04	)

Subsequent events: The Company evaluates events through the date the condensed consolidated financial statements are filed for events requiring adjustment to or disclosure in the consolidated financial statements.

Revenue Recognition	6 Months Ended
Revenue Recognition	Jun. 30, 2022
Revenue Recognition [Abstract]
Revenue Recognition	Note 2 – Revenue Recognition Net Sales: The Company sells its products in the United States primarily through a direct sales force. Customers who purchase the Company’s products include hospitals and clinics throughout the United States. In countries outside the United States, the Company sells its products through a limited number of specialty healthcare distributors in Austria, Brazil, Columbia, The Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, United Arab Emirates, and the United Kingdom. These distributors resell the Company’s products to hospitals and clinics in their respective geographies. Revenue from product sales is recognized when the customer or distributor obtains control of the product, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. The Company’s standard shipping terms are FOB shipping point unless the customer requests that control and title to the inventory transfer upon delivery. Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. The majority of the Company’s contracts have a single performance obligation and are short term in nature. The Company has entered into extended service plans with customers whose related revenue is recognized over time. This revenue represents less than 1% of net sales for the three and six months ended June 30, 2022, and 2021. The unfulfilled performance obligations related to these extended service plans are included in deferred revenue, which is included in other current liabilities on the consolidated balance sheets. The majority of the deferred revenue is expected to be recognized within one year. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Revenue includes shipment and handling fees charged to customers. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold. Product Returns: The Company offers customers a limited right of return for its product in case of non-conformity or performance issues. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and its own historical sales and returns information. The Company has not received any returns to date and believes that future returns of its products will be minimal. Therefore, revenue recognized is not currently impacted by variable consideration related to product returns.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2022
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 3 – Stockholders’ Equity Series F Convertible Preferred Stock: On November 27, 2017, the Company closed on an underwritten public offering Series F convertible preferred stock and warrants to purchase shares of common stock for gross proceeds of $18.0 million. Net proceeds totaled approximately $16.2 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The offering was comprised of Series F convertible preferred stock, convertible into shares of the Company’s common stock at an initial conversion price of $1,890.00 per share. Each share of Series F convertible preferred stock was accompanied by a Series 1 warrant (which expired on the first anniversary of its issuance) to purchase 16 shares of the Company’s common stock at an exercise price of $1,890.00 per share, and a Series 2 warrant, which expires on the seventh anniversary of its issuance, to purchase 16 shares of the Company’s common stock at an exercise price of $1,890.00 per share. The Series F convertible preferred stock has full ratchet price based anti-dilution protection, subject to customary carve outs, in the event of a down-round financing at a price per share below the conversion price of the Series F convertible preferred stock (which protection will expire if, during any 20 of 30 consecutive trading days, the volume weighted average price of the Company’s common stock exceeds 300% of the then-effective conversion price of the Series F convertible preferred stock and the daily dollar trading volume for each trading day during such period exceeds $200,000). The exercise price of the warrants is fixed and does not contain any variable pricing features, nor any price-based anti-dilutive features, apart from customary adjustments for stock splits, combinations, reclassifications, stock dividends or fundamental transactions. A total of 18,000 shares of Series F convertible preferred stock initially convertible into 9,557 shares of common stock and warrants to purchase 19,122 shares of common stock were issued in the offering. Effective March 12, 2019, the conversion price of the Series F convertible preferred stock was reduced from $890.40 to $157.50, the per share price to the public of the Series G convertible preferred stock issued in the March 2019 Offering. Effective October 25, 2019, the conversion price of the Series F convertible preferred stock was reduced from $157.50 to $42.30, and further reduced on November 6, 2019, from $42.30 to $29.83, the per share price to the public in the October and November 2019 transactions, respectively. Effective January 28, 2020, the conversion price of the Series F convertible preferred stock was reduced from $29.83 to $16.50, the per share price to the public of the Series H convertible preferred stock which closed in an underwritten public offering on January 28, 2020, described below. Effective March 23, 2020, the conversion price of the Series F convertible preferred stock was reduced from $16.50 to $9.00, the per share price to the public in the March 2020 transaction, described below. In connection with the September 2021 offering, the conversion price of the Series F convertible preferred stock was reduced from $5.50 to $2.50, the per share price to the public in the September 2021 offering, described below. As of June 30, 2022, and December 31, 2021, 127 shares of the Series F convertible preferred stock remained outstanding. March 2021 Offering: On March 19, 2021, the Company closed on an underwritten public offering of 3,795,816 shares of common stock, for gross proceeds of approximately $20.9 million (the “March 2021 Offering”). Net proceeds totaled approximately $18.9 million after deducting the underwriting discounts and commissions and other costs associated with the offering and after giving effect to the underwriters’ full exercise of their overallotment option. In connection with the March 2021 Offering, the conversion price of the Series F convertible preferred stock was reduced from $9.00 to $5.50, the per share price to the public in the March 2021 Offering. In addition, the exercise price of the common stock warrants issued in connection with the January 2020 Offering was reduced from $9.00 to $5.50, the per share price to the public in the March 2021 Offering. September 2021 Offering: On September 17, 2021, the Company closed on an underwritten public offering of 4,005,588 shares of common stock, for gross proceeds of approximately $10.0 million (the “September 2021 Offering”). Net proceeds totaled approximately $9.0 million after deducting the underwriting discounts and commissions and other costs associated with the offering and after giving effect to the underwriters’ full exercise of their overallotment option. In connection with the September 2021 Offering, the conversion price of the Series F convertible preferred stock was reduced from $5.50 to $2.50, the per share price to the public in the September 2021 Offering. In addition, the exercise price of the common stock warrants issued in connection with the January 2020 Offering was reduced from $5.50 to $2.50, the per share price to the public in the September 2021 Offering. Placement Agent Fees: In connection with the offerings described above, the Company paid the placement agent an aggregate cash placement fee equal to 8% of the aggregate gross proceeds raised in each of the offerings. Market-Based Warrants: On May 30, 2019, the Company granted a market-based warrant to a consultant in exchange for investor relations services. The warrant represents the right to acquire up to 3,334 shares of the Company’s common stock at an exercise price of $95.40 per share, the closing stock price of the Company’s common shares on May 30, 2019. The warrant is subject to a vesting schedule based on the Company achieving certain market stock prices within a specified period of time. The warrant expires on May 30, 2024. The warrant was valued at $57.90 per share using the Monte Carlo valuation methodology and was expensed over the term of the consulting engagement which was twelve months. Significant inputs used for the Monte Carlo valuation were the expected stock price volatility of 136.21%, and management’s expectations regarding the timing of regulatory clearance for an expanded label in pediatrics. None of these warrants had vested as of June 30, 2022. Reverse Stock Split: On October 6, 2020, the Company’s stockholders approved a reverse split of its outstanding common stock at a ratio in the range of 1-for-5 to 1-for-30 and, on October 9, 2020, the board of directors approved a 1-for-30 reverse split of the Company’s outstanding common stock that became effective after trading on October 16, 2020. This reverse stock split did not change the par value of the Company’s common stock or the number of common or preferred shares authorized by the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended. All share and per-share amounts have been retroactively adjusted to reflect the reverse stock splits for all periods presented.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Stock-Based Compensation

6 Months Ended

Jun. 30, 2022

Stock-Based Compensation [Abstract]

Stock-Based Compensation

Note 4 - Stock-Based Compensation

Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation, the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period.

The following table presents the classification of stock-based compensation expense recognized for the periods below:

	Three months ended June 30,				Six months ended June 30,
(in thousands)	2022		2021		2022		2021
Selling, general and administrative expense	$	211	$	350	$	425	$	677
Research and development expense		25		31		52		59
Total stock-based compensation expense	$	236	$	381	$	477	$	736

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2022
Income Taxes [Abstract]
Income Taxes	Note 5 – Income Taxes The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying condensed consolidated financial statements. As of June 30, 2022, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties in its Annual Report on Form 10-K for the year ended December 31, 2021.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Operating Leases	6 Months Ended
Operating Leases	Jun. 30, 2022
Operating Leases [Abstract]
Operating Leases	Note 6—Operating Leases The Company leases a 23,000 square foot facility located in Eden Prairie, Minnesota for office and manufacturing space under a non-cancelable operating lease that expires in March 2027. In November 2021, the Company entered into a fourth amendment to the lease, extending the term of the lease from March 31, 2022 to March 31, 2027. This facility serves as our corporate headquarters and houses substantially all of our functional areas. Monthly rent and common area maintenance charges, including estimated property tax for our headquarters total approximately $29,000. The lease contains provisions for annual inflationary adjustments. Rent expense is being recorded on a straight-line basis over the term of the lease. Beginning on April 1, 2022, the annual base rent is $10.50 per square foot, subject to annual increases of $0.32 to $0.34 per square foot.

Finance Lease Liability	6 Months Ended
Finance Lease Liability	Jun. 30, 2022
Finance Lease Liability [Abstract]
Finance Lease Liability	Note 7—Finance Lease Liability In 2020, the Company entered into lease agreements to finance equipment valued at $98,000. The equipment consisted of computer hardware and audio-visual equipment and is included in Property, Plant and Equipment in the accompanying consolidated financial statements. The principal amount under the lease agreements was $93,000 at the date the lease commenced, the implied interest rate is 7.5%, and the term of the lease is 39 months.

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2022
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 8—Commitments and Contingencies Employee Retirement Plan: The Company has a 401(k) profit-sharing plan that provides retirement benefits to substantially all full-time U.S. employees. Eligible employees may contribute a percentage of their annual compensation, subject to Internal Revenue Service (“IRS”) limitations, with the Company matching a portion of the employees’ contributions at the discretion of the Company. Non-refundable Technology License Fee: On June 24, 2021, the Company entered into a research and development collaboration agreement with Koronis Biomedical Corporation (KBT) to design and develop an integrated continuous renal replacement therapy device. This agreement became effective on August 5, 2021, when KBT received approval of a $1.7 million grant from the National Institutes of Health (NIH) to support this project. As part of this agreement, the Company pays KBT a non-refundable technology license fee of $428,160, payable in twelve equal monthly installments commencing on June 1, 2022. The Company has recorded a liability for the non-refundable technology license fee with $392,480 included in Current Accounts Payable. The full amount of $428,160 was expensed and included in the Research and Development Expense line for the year ended December 31, 2021.

Nature of Business and Basis of Presentation (Policies)

6 Months Ended

Jun. 30, 2022

Nature of Business and Basis of Presentation [Abstract]

Principles of Consolidation

(in thousands)	June 30, 2022		December 31, 2021
Finished Goods	$	1,196	$	1,409
Work in Process		172		276
Raw Materials		1,642		1,158
Total	$	3,010	$	2,843

Loss per Share

	June 30,
	2022		2021

Stock options		1,197,892		812,561
Warrants to purchase common stock		1,630,627		1,631,806
Series F convertible preferred stock		50,800		23,114
Total		2,879,319		2,467,481

The following table reconciles reported net loss with reported net loss per share for each of the three and six months ended June 30:

	Three months ended June 30,						Six months ended June 30,
	2022			2021			2022			2021
(in thousands, except per share amounts)
Net loss	$	(4,286	)	$	(4,731	)	$	(8,759	)	$	(9,952	)
Deemed dividend to preferred shareholders (see note 3)		—			—			—			(33	)
Net loss after deemed dividend		(4,286	)		(4,731	)		(8,759	)		(9,985	)
Weighted average shares outstanding		10,538			6,532			10,538			4,887
Basic and diluted loss per share	$	(0.41	)	$	(0.72	)	$	(0.83	)	$	(2.04	)

Subsequent events

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

+ Details

Nature of Business and Basis of Presentation (Tables)

6 Months Ended

Jun. 30, 2022

Nature of Business and Basis of Presentation [Abstract]

Inventories

Inventories consisted of the following:

(in thousands)	June 30, 2022		December 31, 2021
Finished Goods	$	1,196	$	1,409
Work in Process		172		276
Raw Materials		1,642		1,158
Total	$	3,010	$	2,843

Potential Shares of Common Stock not Included in Diluted Net Loss Per Share

	June 30,
	2022		2021

Stock options		1,197,892		812,561
Warrants to purchase common stock		1,630,627		1,631,806
Series F convertible preferred stock		50,800		23,114
Total		2,879,319		2,467,481

Reconciliation of Reported Net Loss with Reported Net Loss Per Share

The following table reconciles reported net loss with reported net loss per share for each of the three and six months ended June 30:

	Three months ended June 30,						Six months ended June 30,
	2022			2021			2022			2021
(in thousands, except per share amounts)
Net loss	$	(4,286	)	$	(4,731	)	$	(8,759	)	$	(9,952	)
Deemed dividend to preferred shareholders (see note 3)		—			—			—			(33	)
Net loss after deemed dividend		(4,286	)		(4,731	)		(8,759	)		(9,985	)
Weighted average shares outstanding		10,538			6,532			10,538			4,887
Basic and diluted loss per share	$	(0.41	)	$	(0.72	)	$	(0.83	)	$	(2.04	)

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Stock-Based Compensation [Abstract]

Classification of Stock-Based Compensation Expense

The following table presents the classification of stock-based compensation expense recognized for the periods below:

	Three months ended June 30,				Six months ended June 30,
(in thousands)	2022		2021		2022		2021
Selling, general and administrative expense	$	211	$	350	$	425	$	677
Research and development expense		25		31		52		59
Total stock-based compensation expense	$	236	$	381	$	477	$	736

Nature of Business and Basis of Presentation, Nature of Business, Going Concern, Accounts Receivable and Inventories (Details)		3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 17, 2021 USD ($)	Jun. 30, 2022 USD ($) Customer	Jun. 30, 2021 Customer	Jun. 30, 2022 USD ($) Customer	Jun. 30, 2021 USD ($) Customer	Dec. 31, 2021 USD ($) Customer
Going Concern [Abstract]
Accumulated deficit		$ (261,675,000)		$ (261,675,000)		$ (252,916,000)
Net proceeds from issuance of convertible preferred stock	$ 27,900,000
Proceeds from exercise of investor warrants				$ 0	$ 1,300
Revenue Recognition and Accounts Receivable [Abstract]
Accounts receivables maximum credit period from invoice date				30 days
Allowance for doubtful accounts		0		$ 0		0
Inventories [Abstract]
Finished Goods		1,196,000		1,196,000		1,409,000
Work in Process		172,000		172,000		276,000
Raw Materials		1,642,000		1,642,000		1,158,000
Total		$ 3,010,000		$ 3,010,000		$ 2,843,000
Accounts Receivable [Member]
Revenue Recognition and Accounts Receivable [Abstract]
Number of major customers \| Customer				2		2
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Revenue Recognition and Accounts Receivable [Abstract]
Concentration risk percentage				19.00%		12.00%
Customer Two [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Revenue Recognition and Accounts Receivable [Abstract]
Concentration risk percentage				16.00%		11.00%
ASC 606 [Member] \| Net Sales [Member]
Revenue Recognition and Accounts Receivable [Abstract]
Number of major customers \| Customer		3	0	2	2
ASC 606 [Member] \| Customer One [Member] \| Net Sales [Member] \| Customer Concentration Risk [Member]
Revenue Recognition and Accounts Receivable [Abstract]
Concentration risk percentage		14.00%		14.00%	11.00%
ASC 606 [Member] \| Customer Two [Member] \| Net Sales [Member] \| Customer Concentration Risk [Member]
Revenue Recognition and Accounts Receivable [Abstract]
Concentration risk percentage		13.00%		12.00%	11.00%
ASC 606 [Member] \| Customer Three [Member] \| Net Sales [Member] \| Customer Concentration Risk [Member]
Revenue Recognition and Accounts Receivable [Abstract]
Concentration risk percentage		10.00%

Nature of Business and Basis of Presentation, Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Loss per share [Abstract]
Net deemed dividends resulting from subsequent reduction in exercise price of warrants						$ 33
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					2,879,319	2,467,481
Reported net loss with reported net loss per share [Abstract]
Net loss	$ (4,286)	$ (4,473)	$ (4,731)	$ (5,221)	$ (8,759)	$ (9,952)
Deemed dividend to preferred shareholders (see note 3)	0		0		0	(33)
Net loss after deemed dividend	$ (4,286)		$ (4,731)		$ (8,759)	$ (9,985)
Weighted average shares outstanding - basic (in shares)	10,538,000		6,532,000		10,538,000	4,887,000
Weighted average shares outstanding - diluted (in shares)	10,538,000		6,532,000		10,538,000	4,887,000
Basic loss per share (in dollars per share)	$ (0.41)		$ (0.72)		$ (0.83)	$ (2.04)
Diluted loss per share (in dollars per share)	$ (0.41)		$ (0.72)		$ (0.83)	$ (2.04)
Stock Options [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					1,197,892	812,561
Warrants to Purchase Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					1,630,627	1,631,806
Series F Convertible Preferred Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					50,800	23,114

Revenue Recognition (Details)	3 Months Ended		6 Months Ended
Revenue Recognition (Details)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract]
Expected timing of satisfaction, period	1 year		1 year
Sales Revenue [Member] \| Customer Concentration Risk [Member] \| ASC 606 [Member] \| Maximum [Member]
Revenue, Performance Obligation [Abstract]
Percentage of net sales	1.00%	1.00%	1.00%	1.00%

Stockholders' Equity (Details)							6 Months Ended
Stockholders' Equity (Details)	Sep. 17, 2021 USD ($) $ / shares shares	Mar. 19, 2021 USD ($) $ / shares shares	Oct. 09, 2020	Oct. 06, 2020	Mar. 12, 2019 $ / shares	Nov. 27, 2017 USD ($) $ / shares shares	Jun. 30, 2022 $ / shares shares	Dec. 31, 2021 shares	Mar. 23, 2020 $ / shares	Jan. 28, 2020 $ / shares	Nov. 06, 2019 $ / shares	Oct. 25, 2019 $ / shares	May 30, 2019 $ / shares shares	Jul. 03, 2018 $ / shares
Class of Stock Disclosures [Abstract]
Net proceeds from issuance of convertible preferred stock \| $	$ 27,900,000
Preferred stock, shares outstanding (in shares) \| shares							0	0
Reverse stock split			0.03
Minimum [Member]
Class of Stock Disclosures [Abstract]
Reverse stock split				0.2
Maximum [Member]
Class of Stock Disclosures [Abstract]
Reverse stock split				0.03
Expected Stock Price Volatility [Member]
Class of Stock Disclosures [Abstract]
Warrants measurement input							1.3621
March 2021 Offering [Member]
Class of Stock Disclosures [Abstract]
Issuance of common stock, net (in shares) \| shares		3,795,816
Gross proceeds from public stock offering \| $		$ 20,900,000
Net proceeds from public stock offering \| $		$ 18,900,000
September 2021 Offering [Member]
Class of Stock Disclosures [Abstract]
Issuance of common stock, net (in shares) \| shares	4,005,588
Gross proceeds from public stock offering \| $	$ 10,000,000.0
Net proceeds from public stock offering \| $	$ 9,000,000.0
Warrants to Purchase Common Stock [Member]
Class of Stock Disclosures [Abstract]
Number of warrants vested (in shares) \| shares							0
Warrants to Purchase Common Stock [Member] \| Consultant [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares) \| shares													3,334
Exercise price of warrants (in dollars per share)							$ 57.90						$ 95.40
Series F Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Gross proceeds from issuance of convertible preferred stock \| $						$ 18,000,000.0
Net proceeds from issuance of convertible preferred stock \| $						$ 16,200,000
Conversion price (in dollars per share)						$ 1,890.00								$ 890.40
Number of consecutive trading days considered for expiration							20 days
Number of consecutive trading days							30 days
Preferred stock issued (in shares) \| shares						18,000	127	127
Number of shares issuable on conversion of preferred stock (in shares) \| shares						9,557
Preferred stock, shares outstanding (in shares) \| shares							127	127
Aggregate cash placement fee					8.00%
Series F Convertible Preferred Stock [Member] \| Minimum [Member]
Class of Stock Disclosures [Abstract]
Percentage of volume weighted average price of common stock						300.00%
Trading volume for each trading day \| $						$ 200,000
Series F Convertible Preferred Stock [Member] \| March 2019 Offering [Member]
Class of Stock Disclosures [Abstract]
Conversion price (in dollars per share)					$ 157.50
Series F Convertible Preferred Stock [Member] \| October 2019 Offering [Member]
Class of Stock Disclosures [Abstract]
Conversion price (in dollars per share)												$ 42.30
Series F Convertible Preferred Stock [Member] \| November 2019 Offering [Member]
Class of Stock Disclosures [Abstract]
Conversion price (in dollars per share)											$ 29.83
Series F Convertible Preferred Stock [Member] \| January 2020 Offering [Member]
Class of Stock Disclosures [Abstract]
Conversion price (in dollars per share)										$ 16.50
Exercise price of warrants (in dollars per share)										$ 9.00
Series F Convertible Preferred Stock [Member] \| March 2020 Offering [Member]
Class of Stock Disclosures [Abstract]
Conversion price (in dollars per share)									$ 9.00
Series F Convertible Preferred Stock [Member] \| March 2021 Offering [Member]
Class of Stock Disclosures [Abstract]
Conversion price (in dollars per share)		$ 5.50
Exercise price of warrants (in dollars per share)		$ 5.50
Series F Convertible Preferred Stock [Member] \| September 2021 Offering [Member]
Class of Stock Disclosures [Abstract]
Conversion price (in dollars per share)	$ 2.50
Exercise price of warrants (in dollars per share)	$ 2.50
Series F Convertible Preferred Stock [Member] \| Warrants to Purchase Common Stock [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares) \| shares						19,122
Series F Convertible Preferred Stock [Member] \| Warrant Series 1 [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares) \| shares						16
Exercise price of warrants (in dollars per share)						$ 1,890.00
Series F Convertible Preferred Stock [Member] \| Warrant Series 2 [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares) \| shares						16
Exercise price of warrants (in dollars per share)						$ 1,890.00

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 236	$ 381	$ 477	$ 736
Selling, General and Administrative Expense [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	211	350	425	677
Research and Development Expense [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 25	$ 31	$ 52	$ 59

Operating Leases (Details)	6 Months Ended
Operating Leases (Details)	Jun. 30, 2022 USD ($) ft² $ / ft²
Operating Lease s [Abstract]
Area of property leased under operating lease \| ft²	23,000
Monthly rent and common area maintenance charges \| $	$ 29,000
Annual base rent (per square foot)	10.50
Minimum [Member]
Operating Lease s [Abstract]
Annual increase per square foot (in dollars per square foot)	0.32
Maximum [Member]
Operating Lease s [Abstract]
Annual increase per square foot (in dollars per square foot)	0.34

Finance Lease Liability (Details)	Dec. 31, 2020 USD ($)
Finance Lease Liability [Abstract]
Value of finance lease equipment	$ 98,000
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net
Principal amount under lease agreement	$ 93,000
Implied interest rate	7.50%
Finance lease term	39 months

Commitments and Contingencies (Details) - Koronis Biomedical Corporation [Member]		12 Months Ended
	Aug. 05, 2021 USD ($) Installment	Dec. 31, 2021 USD ($)	Jun. 30, 2022 USD ($)
Commitments and Contingencies [Abstract]
Amount of grant approval received	$ 1,700,000
Non-refundable technology license fee	$ 428,160
Number of equal monthly installments \| Installment	12
Research and Development Expense [Member]
Commitments and Contingencies [Abstract]
Non-refundable technology license fee expenses		$ 428,160
Current Accounts Payable [Member]
Commitments and Contingencies [Abstract]
Non-refundable technology license fee			$ 392,480